


# Product Data Sheet

# Compound Name

## Erlotinib

# Structure



#### CAS Number

[183321-74-6]

# Chemical Formula:

 $C_{22}H_{24}ClN_3O_4$ 

Molecular Weight: 429.9

### Background information

Mode of Action	Tyrosine kinase inhibitor
Predominant Target(s)	EGFR
Published Activity	For the treatment of advanced NSCLC.
Development stage	Phase II trials

# References

- 1. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Gupta R, Dastane AM, Forozan F, Riley-Portuguez A, Chung F, Lopategui J, Marchevsky AM. Mod. Pathol. 2008. [Epub ahead of print]
- 2. Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. Herbst RS, Sandler A. Oncologist. 2008. [Epub ahead of print]